Aduro BioTech (ADRO) Rating Lowered to Strong Sell at BidaskClub

BidaskClub lowered shares of Aduro BioTech (NASDAQ:ADRO) from a sell rating to a strong sell rating in a report published on Saturday, February 3rd.

Several other equities analysts have also weighed in on ADRO. ValuEngine lowered shares of Aduro BioTech from a sell rating to a strong sell rating in a report on Friday, February 2nd. Canaccord Genuity set a $30.00 target price on shares of Aduro BioTech and gave the company a buy rating in a report on Thursday, December 14th. HC Wainwright set a $18.00 target price on shares of Aduro BioTech and gave the company a buy rating in a report on Wednesday, November 1st. Finally, Oppenheimer reduced their target price on shares of Aduro BioTech from $15.00 to $13.00 and set an outperform rating on the stock in a report on Wednesday, December 13th. Two investment analysts have rated the stock with a sell rating, one has issued a hold rating and eight have assigned a buy rating to the company’s stock. Aduro BioTech has an average rating of Buy and a consensus price target of $17.71.

Shares of Aduro BioTech (NASDAQ:ADRO) traded up $0.05 on Friday, hitting $6.10. 886,973 shares of the company’s stock were exchanged, compared to its average volume of 538,847. The firm has a market cap of $471.55, a price-to-earnings ratio of -4.49 and a beta of 3.01. Aduro BioTech has a 52 week low of $5.82 and a 52 week high of $14.05.

In related news, EVP Dirk G. Brockstedt sold 5,877 shares of Aduro BioTech stock in a transaction on Monday, November 13th. The shares were sold at an average price of $8.00, for a total transaction of $47,016.00. Following the sale, the executive vice president now owns 75,533 shares of the company’s stock, valued at approximately $604,264. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Also, VP Jennifer Lew sold 6,600 shares of Aduro BioTech stock in a transaction on Friday, December 1st. The stock was sold at an average price of $9.46, for a total transaction of $62,436.00. Following the sale, the vice president now directly owns 68,938 shares in the company, valued at approximately $652,153.48. The disclosure for this sale can be found here. Insiders have sold a total of 205,176 shares of company stock worth $1,752,625 in the last 90 days. Company insiders own 6.60% of the company’s stock.

A number of institutional investors have recently added to or reduced their stakes in the stock. Harvard Management Co. Inc. bought a new stake in shares of Aduro BioTech in the 3rd quarter worth about $69,418,000. Vanguard Group Inc. increased its position in shares of Aduro BioTech by 5.4% in the 2nd quarter. Vanguard Group Inc. now owns 2,511,995 shares of the biotechnology company’s stock worth $28,637,000 after purchasing an additional 129,079 shares during the last quarter. State Street Corp increased its position in shares of Aduro BioTech by 8.3% in the 2nd quarter. State Street Corp now owns 684,699 shares of the biotechnology company’s stock worth $7,808,000 after purchasing an additional 52,597 shares during the last quarter. Baillie Gifford & Co. increased its position in shares of Aduro BioTech by 30.8% in the 3rd quarter. Baillie Gifford & Co. now owns 553,090 shares of the biotechnology company’s stock worth $5,891,000 after purchasing an additional 130,390 shares during the last quarter. Finally, Northern Trust Corp increased its position in shares of Aduro BioTech by 15.1% in the 2nd quarter. Northern Trust Corp now owns 453,115 shares of the biotechnology company’s stock worth $5,166,000 after purchasing an additional 59,490 shares during the last quarter. 45.14% of the stock is currently owned by hedge funds and other institutional investors.

TRADEMARK VIOLATION WARNING: “Aduro BioTech (ADRO) Rating Lowered to Strong Sell at BidaskClub” was originally published by The Ledger Gazette and is the sole property of of The Ledger Gazette. If you are reading this report on another publication, it was copied illegally and republished in violation of international copyright and trademark laws. The legal version of this report can be viewed at https://ledgergazette.com/2018/02/11/aduro-biotech-adro-downgraded-by-bidaskclub-to-strong-sell.html.

About Aduro BioTech

Aduro Biotech, Inc is an immunotherapy company, which focuses on the discovery, development and commercialization of therapies that manage the treatment of various diseases, including cancer. The Company’s product candidates from its Live, Attenuated, Double-Deleted (LADD) Listeria monocytogenes, Stimulator of Interferon Genes Pathway Activator, and B-select monoclonal antibody platforms are designed to stimulate and/or regulate innate and adaptive immune responses, either as single agents or in combination with conventional therapies, as well as other immunotherapies.

Analyst Recommendations for Aduro BioTech (NASDAQ:ADRO)

Receive News & Ratings for Aduro BioTech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aduro BioTech and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply